Welcome to DukeHealth.org.
Skip over navigation
Skip over navigation
- Home
- Patient and Visitor Info
- Physicians
- Services
- Clinical Trials
- Event Calendar
- Locations
- Health Library
- About Duke Medicine
Quick Links
Home
>
Clinical Trials
>
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout who have had an Inadequate Hypouricemic Response to Standard of Care Allopurinol
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout who have had an Inadequate Hypouricemic Response to Standard of Care Allopurinol
In This Section
Related Clinical Trials
Share
Study Goals: To determine the efficacy of an investigational new medication, lesinurad, when used in combination with allopurinol compared to using allopurinol alone.
Age Range: 18-85, inclusive
Number of visits: 17 outpatient visits
Duration: 12 months
Compensation: $50 for each visit, allopurinol and lesinurad/placebo provided free of charge
Drugs/Placebo: Each participant will receive allopurinol (open-label) along with lesinurad or placebo
For more information, contact DCRU Recruitment Team at 919-613-6246.
(REF# 37670)
